FDA Budget for 2027 includes proposal to permanently reauthorize the rare pediatric disease priority review voucher program

The President’s FY2027 FDA budget proposal includes several major legislative reforms aimed at accelerating drug development, modernising regulatory processes, and increasing FDA flexibility.

Key proposals include:

• creation of a new expedited Investigational New Drug (IND) pathway for certain Phase 1 clinical trials where sufficient preclinical data already exists, partly intended to help the U.S. compete with faster early-stage development pathways in countries such as China and Australia.
• permanent reauthorisation of the Rare Pediatric Disease Priority Review Voucher (PRV) program.
• granting the FDA greater discretion over Scientific Advisory Panel composition, including whether industry representatives are appointed to advisory committees.
• providing explicit authority for the FDA to publicly disclose information contained within Complete Response Letters (CRLs), continuing the agency’s recent push toward greater transparency.
• clarifying the legal category and regulatory requirements surrounding compounded drugs, including restrictions on misleading direct-to-consumer advertising.
• removing the requirement for comparative clinical efficacy studies for biosimilars and allowing all biosimilars to be automatically interchangeable with their reference products at the pharmacy level.

Overall, the proposals continue the FDA’s broader shift toward faster review timelines, regulatory flexibility, increased transparency, domestic competitiveness, and reduced development burdens for certain products.

‍

Source: FDA 2027 Fiscal Budget